SEARCH

SEARCH BY CITATION

References

  • Armstrong R. A. (2006) Plaques and tangles and the pathogenesis of Alzheimer’s disease. Folia Neuropathol. 44, 111.
  • Bacskai B. J., Klunk W. E., Mathis C. A. and Hyman B. T. (2002a) Imaging amyloid-beta deposits in vivo. J. Cereb. Blood Flow Metab. 22, 10351041.
  • Bacskai B. J., Kajdasz S. T., McLellan M. E., Games D., Seubert P., Schenk D. and Hyman B. T. (2002b) Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J. Neurosci. 22, 78737878.
  • Bala K., Tripathy B. C. and Sharma D. (2006) Neuroprotective and anti-ageing effects of curcumin in aged rat brain regions. Biogerontology 7, 8189.
  • Bard F., Cannon C., Barbour R. et al. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916919.
  • Behl C. and Moosmann B. (2002) Antioxidant neuroprotection in Alzheimer’s disease as preventive and therapeutic approach. Free Radic. Biol. Med. 33, 182191.
  • Borchelt D. R., Lee M. K., Gonzales V., Slunt H. H., Ratovitski T., Jenkins N. A., Copeland N. G., Price D. L. and Sisodia S. S. (2002) Accumulation of proteolytic fragments of mutant presenilin 1 and accelerated amyloid deposition are co-regulated in transgenic mice. Neurobiol. Aging 23, 171177.
  • Brendza R. P., Bacskai B. J., Cirrito J. R. et al. (2005) Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J. Clin. Invest. 115, 428433.
  • Cheng A. L., Hsu C. H., Lin J. K. et al. (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 21, 28952900.
  • Christen Y. (2000) Oxidative stress and Alzheimer disease. Am. J. Clin. Nutr. 71, 621S629S.
  • Cole G. M., Morihara T., Lim G. P., Yang F., Begum A. and Frautschy S. A. (2004) NSAID and antioxidant prevention of Alzheimer’s disease: lessons from in vitro and animal models. Ann. N. Y. Acad. Sci. 1035, 6884.
  • D’Amore J. D., Kajdasz S. T., McLellan M. E., Bacskai B. J., Stern E. A. and Hyman B. T. (2003) In vivo multiphoton imaging of a transgenic mouse model of Alzheimer disease reveals marked thioflavine-S-associated alterations in neurite trajectories. J. Neuropathol. Exp. Neurol. 62, 137145.
  • Dairam A., Limson J. L., Watkins G. M., Antunes E. and Daya S. (2007) Curcuminoids, curcumin, and demethoxycurcumin reduce lead-induced memory deficits in male Wistar rats. J. Agric. Food Chem. 55, 10391044.
  • El Khoury J., Hickman S. E., Thomas C. A., Loike J. D. and Silverstein S. C. (1998) Microglia, scavenger receptors, and the pathogenesis of Alzheimer’s disease. Neurobiol. Aging 19, S81S84.
  • Frautschy S. A., Hu W., Kim P., Miller S. A., Chu T., Harris-White M. E. and Cole G. M. (2001) Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol. Aging 22, 9931005.
  • Fuentes-Santamaria V., Stein B. E. and McHaffie J. G. (2006) Neurofilament proteins are preferentially expressed in descending output neurons of the cat the superior colliculus: a study using SMI-32. Neuroscience 138, 5568.
  • Garcia-Alloza M., Dodwell S. A., Meyer-Luehmann M., Hyman B. T. and Bacskai B. J. (2006a) Plaque-derived oxidative stress mediates distorted neurite trajectories in the Alzheimer mouse model. J. Neuropathol. Exp. Neurol. 65, 10821089.
  • Garcia-Alloza M., Robbins E. M., Zhang-Nunes S. X., Purcell S. M., Betensky R. A., Raju S., Prada C., Greenberg S. M., Bacskai B. J. and Frosch M. P. (2006b) Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 24, 516524.
  • Hashimoto M. and Masliah E. (2003) Cycles of aberrant synaptic sprouting and neurodegeneration in Alzheimer’s and dementia with Lewy bodies. Neurochem. Res. 28, 17431756.
  • Holt P. R., Katz S. and Kirshoff R. (2005) Curcumin therapy in inflammatory bowel disease: a pilot study. Dig. Dis. Sci. 50, 21912193.
  • Huang X., Atwood C. S., Hartshorn M. A. et al. (1999) The A beta peptide of Alzheimer’s disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38, 76097616.
  • Jankowsky J. L., Xu G., Fromholt D., Gonzales V. and Borchelt D. R. (2003) Environmental enrichment exacerbates amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J. Neuropathol. Exp. Neurol. 62, 12201227.
  • Janus C., Pearson J., McLaurin J. et al. (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature 408, 979982.
  • Jellinger K. A. (2002) Alzheimer disease and cerebrovascular pathology: an update. J. Neural. Transm. 109, 813836.
  • Jung K. K., Lee H. S., Cho J. Y., Shin W. C., Rhee M. H., Kim T. G., Kang J. H., Kim S. H., Hong S. and Kang S. Y. (2006) Inhibitory effect of curcumin on nitric oxide production from lipopolysaccharide-activated primary microglia. Life Sci. 79, 20222031.
  • Kawarabayashi T., Younkin L. H., Saido T. C., Shoji M., Ashe K. H. and Younkin S. G. (2001) Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer’s disease. J. Neurosci. 21, 372381.
  • Kim H. Y., Park E. J., Joe E. H. and Jou I. (2003) Curcumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia. J. Immunol. 171, 60726079.
  • Knowles R. B., Wyart C., Buldyrev S. V., Cruz L., Urbanc B., Hasselmo M. E., Stanley H. E. and Hyman B. T. (1999) Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer’s disease. Proc. Natl. Acad. Sci. U. S. A. 96, 52745279.
  • Le R., Cruz L., Urbanc B., Knowles R. B., Hsiao-Ashe K., Duff K., Irizarry M. C., Stanley H. E. and Hyman B. T. (2001) Plaque-induced abnormalities in neurite geometry in transgenic models of Alzheimer disease: implications for neural system disruption. J. Neuropathol. Exp. Neurol. 60, 753758.
  • Li Z. H., Lu J., Tay S. S., Wu Y. J., Strong M. J. and He B. P. (2006) Mice with targeted disruption of neurofilament light subunit display formation of protein aggregation in motoneurons and downregulation of complement receptor type 3 alpha subunit in microglia in the spinal cord at their earlier age: a possible feature in pre-clinical development of neurodegenerative diseases. Brain Res. 1113, 200209.
  • Lim G. P., Chu T., Yang F., Beech W., Frautschy S. A. and Cole G. M. (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 21, 83708377.
  • Lombardo J. A., Stern E. A., McLellan M. E., Kajdasz S. T., Hickey G. A., Bacskai B. J. and Hyman B. T. (2003) Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J. Neurosci. 23, 1087910883.
  • McLellan M. E., Kajdasz S. T., Hyman B. T. and Bacskai B. J. (2003) In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J. Neurosci. 23, 22122217.
  • O’Brien J. T., Erkinjuntti T., Reisberg B. et al. (2003) Vascular cognitive impairment. Lancet Neurol. 2, 8998.
  • Ono K., Hasegawa K., Naiki H. and Yamada M. (2004) Curcumin has potent anti-amyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitro. J. Neurosci. Res. 75, 742750.
  • Robbins E. M., Betensky R. A., Domnitz S. B. et al. (2006) Kinetics of cerebral amyloid angiopathy progression in a transgenic mouse model of Alzheimer disease. J. Neurosci. 26, 365371.
  • Ryu E. K., Choe Y. S., Lee K. H., Choi Y. and Kim B. T. (2006) Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J. Med. Chem. 49, 61116119.
  • Selkoe D. J. (1994) Alzheimer’s disease: a central role for amyloid. J. Neuropathol. Exp. Neurol. 53, 438447.
  • Shukla P. K., Khanna V. K., Khan M. Y. and Srimal R. C. (2003) Protective effect of curcumin against lead neurotoxicity in rat. Hum. Exp. Toxicol. 22, 653658.
  • Simard A. R., Soulet D., Gowing G., Julien J. P. and Rivest S. (2006) Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer’s disease. Neuron 49, 489502.
  • Skoch J., Hyckey G. A., Kajdasz S. T., Hyman B. T. and Bacskai B. J. (2005) In vivo imaging of amyloid-ß deposits in mouse brain with multiphoton microscopy, in Methods in Molecular Biology, Vol. 299 (SigurdsonE. M., ed.), pp. 349364. Humana Press, Totowa, NJ, USA.
  • Spires T. L., Meyer-Luehmann M., Stern E. A., McLean P. J., Skoch J., Nguyen P. T., Bacskai B. J. and Hyman B. T. (2005) Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J. Neurosci. 25, 72787287.
  • Stern E. A., Bacskai B. J., Hickey G. A., Attenello F. J., Lombardo J. A. and Hyman B. T. (2004) Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. J. Neurosci. 24, 45354540.
  • Walker E. S., Martinez M., Brunkan A. L. and Goate A. (2005) Presenilin 2 familial Alzheimer’s disease mutations result in partial loss of function and dramatic changes in Abeta 42/40 ratios. J. Neurochem. 92, 294301.
  • Wilcock D. M., DiCarlo G., Henderson D., Jackson J., Clarke K., Ugen K. E., Gordon M. N. and Morgan D. (2003) Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. 23, 37453751.
  • Yang F., Lim G. P., Begum A. N. et al. (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280, 58925901.